A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis

Is this Study for You?

Let's Get Started!


This study will compare how well the study drug works in slowing the progression of kidney disease and how safe the study drug is when compared to placebo in chronic kidney disease patients with metabolic acidosis. The average duration of the study is anticipated to be about 3.5 years.




Male and female subjects between 18 - 85, inclusive GFR between 20 and 40 ml/min/1.73 m2, inclusive Serum Bicarbonate between 12 and 20 mEq/L, inclusive Systolic blood pressure <160/92

Type of Study

Outcomes Research


Colorado Research Center
Renal Research Center

Principal Investigator
Photograph of Jessica Kendrick,  MD

Jessica Kendrick, MD

Study ID

Protocol Number: 18-1795

More information available at ClinicalTrials.gov: NCT03710291

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers